Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Pediatric Nephrology
Published in: Pediatric Nephrology 6/2011

01-06-2011 | Review

Clinical and Molecular Insights into Tuberous Sclerosis Complex Renal Disease

Authors: Brian J. Siroky, Hong Yin, John J. Bissler

Published in: Pediatric Nephrology | Issue 6/2011

Login to get access

Abstract

Patients with tuberous sclerosis complex are at great risk of developing renal lesions as part of their disease. These lesions include renal cysts and tumors. Significant advances in understanding the cell biology of these renal lesions has already led to clinical trials demonstrating that pharmacological interventions are likely possible. This review focuses on the pathology of these renal lesions, their underlying cell biology, and the possible therapeutic strategies that may prove to significantly improve care for these patients.
Literature
1.
Gomez M, Sampson J, Whittemore V (1999) Tuberous sclerosis. Oxford University Press, New York
2.
Shepherd CW, Gomez MR, Lie JT, Crowson CS (1991) Causes of death in patients with tuberous sclerosis. Mayo Clin Proc 66:792–796PubMed
3.
Dabora SL, Jozwiak S, Franz DN, Roberts PS, Nieto A, Chung J, Choy YS, Reeve MP, Thiele E, Egelhoff JC, Kasprzyk-Obara J, Domanska-Pakiela D, Kwiatkowski DJ (2001) Mutational analysis in a cohort of 224 tuberous sclerosis patients indicates increased severity of TSC2, compared with TSC1, disease in multiple organs. Am J Hum Genet 68:64–80PubMed
4.
Ewalt DH, Sheffield E, Sparagana SP, Delgado MR, Roach ES (1998) Renal lesion growth in children with tuberous sclerosis complex. J Urol 160:141–145PubMed
5.
Rakowski SK, Winterkorn EB, Paul E, Steele DJ, Halpern EF, Thiele EA (2006) Renal manifestations of tuberous sclerosis complex: incidence, prognosis, and predictive factors. Kidney Int 70:1777–1782PubMed
6.
Patel V, Li L, Cobo-Stark P, Shao X, Somlo S, Lin F, Igarashi P (2008) Acute kidney injury and aberrant planar cell polarity induce cyst formation in mice lacking renal cilia. Hum Mol Genet 17:1578–1590PubMedPubMedCentral
7.
de Chadarevian JP, Legido A, Miles DK, Katsetos CD (2003) Epilepsy, atherosclerosis, myocardial infarction, and carbamazepine. J Child Neurol 18:150–151PubMed
8.
Brook-Carter PT, Peral B, Ward CJ, Thompson P, Hughes J, Maheshwar MM, Nellist M, Gamble V, Harris PC, Sampson JR (1994) Deletion of the TSC2 and PKD1 genes associated with severe infantile polycystic kidney disease–a contiguous gene syndrome. Nat Genet 8:328–332PubMed
9.
Kozlowski P, Roberts P, Dabora S, Franz D, Bissler J, Northrup H, Au KS, Lazarus R, Domanska-Pakiela D, Kotulska K, Jozwiak S, Kwiatkowski DJ (2007) Identification of 54 large deletions/duplications in TSC1 and TSC2 using MLPA, and genotype-phenotype correlations. Hum Genet 121:389–400PubMed
10.
Sampson JR, Maheshwar MM, Aspinwall R, Thompson P, Cheadle JP, Ravine D, Roy S, Haan E, Berstein J, Harris PC (1997) Renal cystic disease in tuberous sclerosis: role of the polycystic kidney disease 1 gene. Am J Hum Genet 61:843–851PubMedPubMedCentral
11.
Valero Puerta JA, Medina Perez M, Valpuesta Fernandez I, Sanchez Gonzalez M (1999) A simple renal cyst, the origin of Wunderlich's syndrome. Arch Esp Urol 52:794–797PubMed
12.
Bernstein J, Meyer R (1967) Parenchymal maldevelopment of the kidney. In: Kelley V (ed) Brennemann-Kelley practice of pediatrics. Harper, New York, pp 1–30
13.
Potter E (1952) Pathology of the fetus and the newborn. Year Book Medical Publishers, Chicago
14.
Ferrus A, Garcia-Bellido A (1976) Morphogenetic mutants detected in mitotic recombination clones. Nature 260:425–426PubMed
15.
Siroky BJ, Czyzyk-Krzeska MF, Bissler JJ (2009) Renal involvement in tuberous sclerosis complex and von Hippel-Lindau disease: shared disease mechanisms? Nat Clin Pract Nephrol 5:143–156PubMed
16.
17.
Masoumi A, Reed-Gitomer B, Kelleher C, Bekheirnia MR, Schrier RW (2008) Developments in the management of autosomal dominant polycystic kidney disease. Ther Clin Risk Manag 4:393–407PubMedPubMedCentral
18.
Jones AC, Daniells CE, Snell RG, Tachataki M, Idziaszczyk SA, Krawczak M, Sampson JR, Cheadle JP (1997) Molecular genetic and phenotypic analysis reveals differences between TSC1 and TSC2 associated familial and sporadic tuberous sclerosis. Hum Mol Genet 6:2155–2216PubMed
19.
Bernstein J (1993) Renal cystic disease in the tuberous sclerosis complex. Pediatr Nephrol 7:490–495PubMed
20.
21.
Sarnat HB, Flores-Sarnat L (2005) Embryology of the neural crest: its inductive role in the neurocutaneous syndromes. J Child Neurol 20:637–643PubMed
22.
Hao Z, Guo C, Jiang X, Krueger S, Pietri T, Dufour S, Cone RE, O'Rourke J (2006) New transgenic evidence for a system of sympathetic axons able to express tissue plasminogen activator (t-PA) within arterial/arteriolar walls. Blood 108:200–202PubMedPubMedCentral
23.
Henske EP (2005) Tuberous sclerosis and the kidney: from mesenchyme to epithelium, and beyond. Pediatr Nephrol 20:854–857PubMed
24.
Lin F, Yang W, Betten M, The BT, Yang XJ, French Kidney Cancer Study Group (2006) Expression of S-100 protein in renal cell neoplasms. Hum Pathol 37:462–470PubMed
25.
Martignoni G, Pea M, Cossu Rocca P, Bonetti F (2003) Renal pathology in the tuberous sclerosis complex. Pathology 35:505–512PubMed
26.
Bonetti F, Pea M, Martignoni G, Doglioni C, Zamboni G, Capelli P, Rimondi P, Andrion A (1994) Clear cell ("sugar") tumor of the lung is a lesion strictly related to angiomyolipoma–the concept of a family of lesions characterized by the presence of the perivascular epithelioid cells (PEC). Pathology 26:230–236PubMed
27.
El-Hashemite N, Walker V, Zhang H, Kwiatkowski DJ (2003) Loss of Tsc1 or Tsc2 induces vascular endothelial growth factor production through mammalian target of rapamycin. Cancer Res 63:5173–5177PubMed
28.
Karbowniczek M, Yu J, Henske EP (2003) Renal angiomyolipomas from patients with sporadic lymphangiomyomatosis contain both neoplastic and non-neoplastic vascular structures. Am J Pathol 162:491–500PubMedPubMedCentral
29.
O'Callaghan FJ, Harris T, Joinson C, Bolton P, Noakes M, Presdee D, Renowden S, Shiell A, Martyn CN, Osborne JP (2004) The relation of infantile spasms, tubers, and intelligence in tuberous sclerosis complex. Arch Dis Child 89:530–533PubMedPubMedCentral
30.
McCullough DL, Scott R Jr, Seybold HM (1971) Renal angiomyolipoma (hamartoma): review of the literature and report of 7 cases. J Urol 105:32–44PubMed
31.
Stillwell TJ, Gomez MR, Kelalis PP (1987) Renal lesions in tuberous sclerosis. J Urol 138:477–481PubMed
32.
Bernstein J, Robbins TO (1991) Renal involvement in tuberous sclerosis. Ann NY Acad Sci 615:36–49PubMed
33.
Kennelly MJ, Grossman HB, Cho KJ (1994) Outcome analysis of 42 cases of renal angiomyolipoma [see comments]. J Urol 152:1988–1991PubMed
34.
Lemaitre L, Robert Y, Dubrulle F, Claudon M, Duhamel A, Danjou P, Mazeman E (1995) Renal angiomyolipoma: growth followed up with CT and/or US [see comments]. Radiology 197:598–602PubMed
35.
Steiner MS, Goldman SM, Fishman EK, Marshall FF (1993) The natural history of renal angiomyolipoma. J Urol 150:1782–1786PubMed
36.
Pacheco-Rodriguez G, Moss J (2010) The role of chemokines in migration of metastatic-like lymphangioleiomyomatosis cells. Crit Rev Immunol 30:387–394PubMedPubMedCentral
37.
Ou YC, Wu HC, Yang CR, Chang CL, Hwang TI, Chang CH (1991) Renal angiomyolipoma: experience of 23 patients. Chung Hua I Hsueh Tsa Chih Taipei 48:217–223PubMed
38.
Bissler JJ, Racadio J, Donnelly LF, Johnson MD (2002) Reduction of postembolization syndrome after ablation of renal angiomyolipoma. Am J Kidney Dis 39:966–971PubMed
39.
Casper KA, Donnelly LF, Chen B, Bissler JJ (2002) Tuberous sclerosis complex: renal imaging findings. Radiology 225:451–456PubMed
40.
Adler J, Greweldinger J, Litzky G (1984) "Macro" aneurysm in renal angiomyolipoma: two cases, with therapeutic embolization in one patient. Urol Radiol 6:201–203PubMed
41.
Kessler OJ, Gillon G, Neuman M, Engelstein D, Winkler H, Baniel J (1998) Management of renal angiomyolipoma: analysis of 15 cases. Eur Urol 33:572–575PubMed
42.
Mouded IM, Tolia BM, Bernie JE, Newman HR (1978) Symptomatic renal angiomyolipoma: report of 8 cases, 2 with spontaneous rupture. J Urol 119:684–688PubMed
43.
Pode D, Meretik S, Shapiro A, Caine M (1985) Diagnosis and management of renal angiomyolipoma. Urology 25:461–467PubMed
44.
Yamakado K, Tanaka N, Nakagawa T, Kobayashi S, Yanagawa M, Takeda K (2002) Renal angiomyolipoma: relationships between tumor size, aneurysm formation, and rupture. Radiology 225:78–82PubMed
45.
Clarke A, Hancock E, Kingswood C, Osborne JP (1999) End-stage renal failure in adults with the tuberous sclerosis complex. Nephrol Dial Transplant 14:988–991PubMed
46.
Schillinger F, Montagnac R (1996) Chronic renal failure and its treatment in tuberous sclerosis. Nephrol Dial Transplant 11:481–485PubMed
47.
Fox CH, Voleti V, Khan LS, Murray B, Vassalotti J (2008) A quick guide to evidence-based chronic kidney disease care for the primary care physician. Postgrad Med 120:E01–E06PubMed
48.
Patel U, Simpson E, Kingswood JC, Saggar-Malik AK (2005) Tuberose sclerosis complex: analysis of growth rates aids differentiation of renal cell carcinoma from atypical or minimal-fat-containing angiomyolipoma. Clin Radiol 60:665–673, discussion 663-664PubMed
49.
Eble JN, Amin MB, Young RH (1997) Epithelioid angiomyolipoma of the kidney: a report of five cases with a prominent and diagnostically confusing epithelioid smooth muscle component. Am J Surg Pathol 21:1123–1130PubMed
50.
Mai KT, Perkins DG, Collins JP (1996) Epithelioid cell variant of renal angiomyolipoma [see comments]. Histopathology 28:277–280PubMed
51.
Lin CN, Chiang HS, Hsu SI, Huang AH, Chuang SS (1994) Renal angiomyolipoma with a prominent angiomatous component and extramedullary hematopoiesis: a case report. Chung Hua I Hsueh Tsa Chih Taipei 53:185–187PubMed
52.
Tweeddale DN, Dawe CJ, McDonald JR (1955) Angiolipoleiomyoma of the kidney:report of a case with observations on histogenesis. Cancer 8:764–770PubMed
53.
Obuz F, Karabay N, Secil M, Igci E, Kovanlikaya A, Yorukoglu K (2000) Various radiological appearances of angiomyolipomas in the same kidney. Eur Radiol 10:897–899PubMed
54.
Wong AL, McGeorge A, Clark AH (1981) Renal angiomyolipoma: a review of the literature and a report of 4 cases. Br J Urol 53:406–411PubMed
55.
Farrow GM, Harrison EG Jr, Utz DC, Jones DR (1968) Renal angiomyolipoma. A clinicopathologic study of 32 cases. Cancer 22:564–570PubMed
56.
Eble JN (1998) Angiomyolipoma of kidney. Semin Diagn Pathol 15:21–40PubMed
57.
Bjornsson J, Short MP, Kwiatkowski DJ, Henske EP (1996) Tuberous sclerosis-associated renal cell carcinoma. Clinical, pathological, and genetic features. Am J Pathol 149:1201–1208PubMedPubMedCentral
58.
Hardman JA, McNicholas TA, Kirkham N, Fletcher MS (1993) Recurrent renal angiomyolipoma associated with renal carcinoma in a patient with tuberous sclerosis. Br J Urol 72:983–984PubMed
59.
Aydin H, Magi-Galluzzi C, Lane BR, Sercia L, Lopez JL, Rini BL, Zhou M (2009) Renal angiomyolipoma: clinicopathologic study of 194 cases with emphasis on the epithelioid histology and tuberous sclerosis association. Am J Surg Pathol 33:289–297PubMed
60.
Folpe AL, Mentzel T, Lehr HA, Fisher C, Balzer BL, Weiss SW (2005) Perivascular epithelioid cell neoplasms of soft tissue and gynecologic origin: a clinicopathologic study of 26 cases and review of the literature. Am J Surg Pathol 29:1558–1575PubMed
61.
Jimenez RE, Eble JN, Reuter VE, Epstein JI, Folpe AL, de Peralta-Venturina M, Tamboli P, Ansell ID, Grignon DJ, Young RH, Amin MB (2001) Concurrent angiomyolipoma and renal cell neoplasia: a study of 36 cases. Mod Pathol 14:157–163PubMed
62.
Amin MB, Crotty TB, Tickoo SK, Farrow GM (1997) Renal oncocytoma: a reappraisal of morphologic features with clinicopathologic findings in 80 cases. Am J Surg Pathol 21:1–12PubMed
63.
Eble JN, Hull MT (1984) Morphologic features of renal oncocytoma: a light and electron microscopic study. Hum Pathol 15:1054–1061PubMed
64.
Zerban H, Nogueira E, Riedasch G, Bannasch P (1987) Renal oncocytoma: origin from the collecting duct. Virchows Arch B Cell Pathol Incl Mol Pathol 52:375–387PubMed
65.
Siracusano S, Zanon M, D'Aloia G, Plaino F, Trombetta C, Bussani R (1998) Rare association of renal angiomyolipoma and oncocytoma. Urology 51:837–839PubMed
66.
Al-Saleem T, Wessner LL, Scheithauer BW, Patterson K, Roach ES, Dreyer SJ, Fujikawa K, Bjornsson J, Bernstein J, Henske EP (1998) Malignant tumors of the kidney, brain, and soft tissues in children and young adults with the tuberous sclerosis complex. Cancer 83:2208–2216PubMed
67.
Breysem L, Nijs E, Proesmans W, Smet MH (2002) Tuberous sclerosis with cystic renal disease and multifocal renal cell carcinoma in a baby girl. Pediatr Radiol 32:677–680PubMed
68.
Robertson FM, Cendron M, Klauber GT, Harris BH (1996) Renal cell carcinoma in association with tuberous sclerosis in children. J Pediatr Surg 31:729–730PubMed
69.
Lane BR, Aydin H, Danforth TL, Zhou M, Remer EM, Novick AC, Campell SC (2008) Clinical correlates of renal angiomyolipoma subtypes in 209 patients: classic, fat poor, tuberous sclerosis associated and epithelioid. J Urol 180:836–843PubMed
70.
Saito K, Fujii Y, Kasahara I, Kasuga T, Kihara K (2002) Malignant clear cell "sugar" tumor of the kidney: clear cell variant of epithelioid angiomyolipoma. J Urol 168:2533–2534PubMed
71.
Pea M, Bonetti F, Martignoni G, Henske EP, Manfrin E, Colato C, Bernstein J (1998) Apparent renal cell carcinomas in tuberous sclerosis are heterogeneous: the identification of malignant epithelioid angiomyolipoma. Am J Surg Pathol 22:180–187PubMed
72.
Levine AJ, Feng Z, Mak TW, You H, Jin S (2006) Coordination and communication between the p53 and IGF-1-AKT-TOR signal transduction pathways. Genes Dev 20:267–275PubMed
73.
Feng Z, Zhang H, Levine AJ, Jin S (2005) The coordinate regulation of the p53 and mTOR pathways in cells. Proc Natl Acad Sci USA 102:8204–8209PubMed
74.
Jones RG, Plas DR, Kubek S, Buzzai M, Mu J, Xu Y, Birnbaum MJ, Thompson CB (2005) AMP-activated protein kinase induces a p53-dependent metabolic checkpoint. Mol Cell 18:283–293PubMed
75.
Nakamura T, Sakamoto K (2008) Forkhead transcription factor FOXO subfamily is essential for reactive oxygen species-induced apoptosis. Mol Cell Endocrinol 281:47–55PubMed
76.
Nogueira V, Park Y, Chen CC, Xu PZ, Chen ML, Tonic I, Unteman T, Hay N (2008) Akt determines replicative senescence and oxidative or oncogenic premature senescence and sensitizes cells to oxidative apoptosis. Cancer Cell 14:458–470PubMedPubMedCentral
77.
Bissler JJ, McCormack FX, Young LR, Elwing JM, Chuck G, Leonar JM, Schmithorst VJ, Laor T, Brody AS, Bean J, Salisbury S, Franz DN (2008) Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis. N Engl J Med 358:140–151PubMedPubMedCentral
78.
Shillingford JM, Piontek KB, Germino GG, Weimbs T (2010) Rapamycin ameliorates PKD resulting from conditional inactivation of Pkd1. J Am Soc Nephrol 21:489–497PubMedPubMedCentral
79.
Carelli S, Lesma E, Paratore S, Grande V, Zadra G, Bosari S, Di Giulio AM, Gorio A (2007) Survivin expression in tuberous sclerosis complex cells. Mol Med 13:166–177PubMedPubMedCentral
80.
Juul A, Dalgaard P, Blum WF, Bang P, Hall K, MichaelsenKF MJ, Skakkebaek NE (1995) Serum levels of insulin-like growth factor (IGF)-binding protein-3 (IGFBP-3) in healthy infants, children, and adolescents: the relation to IGF-I, IGF-II, IGFBP-1, IGFBP-2, age, sex, body mass index, and pubertal maturation. J Clin Endocrinol Metab 80:2534–2542PubMed
81.
Maggio M, Ble A, Ceda GP, Metter EJ (2006) Decline in insulin-like growth factor-I levels across adult life span in two large population studies. J Gerontol A Biol Sci Med Sci 61:182–183PubMed
82.
Lesma E, Grande V, Ancona S, Carelli S, Di Giulio AM, Gorio A (2008) Anti-EGFR antibody efficiently and specifically inhibits human TSC2/ smooth muscle cell proliferation. Possible treatment options for TSC and LAM. PLoS one 3:e3558PubMedPubMedCentral
83.
Pazour GJ, Witman GB (2003) The vertebrate primary cilium is a sensory organelle. Curr Opin Cell Biol 15:105–110PubMed
84.
Yoder BK, Hou X, Guay-Woodford LM (2002) The polycystic kidney disease proteins, polycystin-1, polycystin-2, polaris, and cystin, are co-localized in renal cilia. J Am Soc Nephrol 13:2508–2516PubMed
85.
Hou X, Mrug M, Yoder BK, Lefkowitz EJ, Kremmidiotis G, D'Eustachio P, BeierDR Guay-Woodford LM (2002) Cystin, a novel cilia-associated protein, is disrupted in the cpk mouse model of polycystic kidney disease. J Clin Invest 109:533–540PubMedPubMedCentral
86.
Lin F, Hiesberger T, Cordes K, Sinclair AM, Goldstein LS, Somlo S, Igarashi P (2003) Kidney-specific inactivation of the KIF3A subunit of kinesin-II inhibits renal ciliogenesis and produces polycystic kidney disease. Proc Natl Acad Sci USA 100:5286–5291PubMed
87.
Cardenas-Rodriguez M, Badano JL (2009) Ciliary biology: understanding the cellular and genetic basis of human ciliopathies. Am J Med Genet C Semin Med Genet 151C:263–280PubMed
88.
Astrinidis A, Senapedis W, Henske EP (2006) Hamartin, the tuberous sclerosis complex 1 gene product, interacts with polo-like kinase 1 in a phosphorylation-dependent manner. Hum Mol Genet 15:287–297PubMed
89.
Distefano G, Boca M, Rowe I, Wodarczyk C, Ma L, Piontek KB, Germino GG, Pandolfi PP, Boletta A (2009) Polycystin-1 regulates extracellular signal-regulated kinase-dependent phosphorylation of tuberin to control cell size through mTOR and its downstream effectors S6K and 4EBP1. Mol Cell Biol 29:2359–2371PubMedPubMedCentral
90.
Kleymenova E, Ibraghimov-Beskrovnaya O, Kugoh H, Everitt J, Xu H, Kiguchi K, Landes G, Harris P, Walker C (2001) Tuberin-dependent membrane localization of polycystin-1: a functional link between polycystic kidney disease and the TSC2 tumor suppressor gene. Mol Cell 7:823–832PubMed
91.
Praetorius HA, Spring KR (2001) Bending the MDCK cell primary cilium increases intracellular calcium. J Membr Biol 184:71–79PubMed
92.
Nauli SM, Alenghat FJ, Luo Y, Williams E, Vassilev P, Li X, Elia AE, Lu W, Brown EM, Quinn SJ, Ingber DE, Zhou J (2003) Polycystins 1 and 2 mediate mechanosensation in the primary cilium of kidney cells. Nat Genet 33:129–137PubMed
93.
Simons M, Gloy J, Ganner A, Bullerkotte A, Bashkurov M, Krönig C, Schermer B, Benzing T, Cabello OA, Jenny A, Mlodzik M, Polok B, Driever W, Obara T, Walz G (2005) Inversin, the gene product mutated in nephronophthisis type II, functions as a molecular switch between Wnt signaling pathways. Nat Genet 37:537–543PubMedPubMedCentral
94.
Bonnet CS, Aldred M, von Ruhland C, Harris R, Sandford R, Cheadle JP (2009) Defects in cell polarity underlie TSC and ADPKD-associated cystogenesis. Hum Mol Genet 18:2166–2176PubMed
95.
Christensen ST, Pedersen LB, Schneider L, Satir P (2007) Sensory cilia and integration of signal transduction in human health and disease. Traffic 8:97–109PubMed
96.
Zhang H, Bajraszewski N, Wu E, Wang H, Moseman AP, Dabora SL, Griffin JD, Kwiatkowski DJ (2007) PDGFRs are critical for PI3K/Akt activation and negatively regulated by mTOR. J Clin Invest 117:730–738PubMedPubMedCentral
97.
Neugebauer JM, Amack JD, Peterson AG, Bisgrove BW, Yost HJ (2009) FGF signalling during embryo development regulates cilia length in diverse epithelia. Nature 458:651–654PubMedPubMedCentral
98.
Meyers EN, Martin GR (1999) Differences in left-right axis pathways in mouse and chick: functions of FGF8 and SHH. Science 285:403–406PubMed
99.
Haycraft CJ, Banizs B, Aydin-Son Y, Zhang Q, Michaud EJ, Yoder BK (2005) Gli2 and Gli3 localize to cilia and require the intraflagellar transport protein polaris for processing and function. PLoS Genet 1:e53PubMedPubMedCentral
100.
Satir P, Christensen ST (2007) Overview of structure and function of mammalian cilia. Annu Rev Physiol 69:377–400PubMed
101.
Guertin DA, Sabatini DM (2007) Defining the role of mTOR in cancer. Cancer Cell 12:9–22PubMed
102.
Manning BD (2004) Balancing Akt with S6K: implications for both metabolic diseases and tumorigenesis. J Cell Biol 167:399–403PubMedPubMedCentral
103.
Jaeschke A, Hartkamp J, Saitoh M, Roworth W, Nobukuni T, Hodges A, Sampson J, Thomas G, Lamb R (2002) Tuberous sclerosis complex tumor suppressor-mediated S6 kinase inhibition by phosphatidylinositide-3-OH kinase is mTOR independent. J Cell Biol 159:217–224PubMedPubMedCentral
104.
Kwiatkowski DJ, Zhang H, Bandura JL, Heiberger KM, Glogauer M, el-Hashemite N, Onda H (2002) A mouse model of TSC1 reveals sex-dependent lethality from liver hemangiomas, and up-regulation of p70S6 kinase activity in Tsc1 null cells. Hum Mol Genet 11:525–534PubMed
105.
Kenerson H, Aicher L, True L, Yeung R (2002) Activated mTOR pathway in the pathogenesis of tuberous sclerosis. In: Whittemore V (ed) New perspectives in tuberous sclerosis complex. TS Alliance, Chantilly
106.
Kenerson HL, Aicher LD, True LD, Yeung RS (2002) Activated Mammalian target of rapamycin pathway in the pathogenesis of tuberous sclerosis complex renal tumors. Cancer Res 62:5645–5650PubMed
107.
Ito N, Rubin GM (1999) Gigas, a Drosophila homolog of tuberous sclerosis gene product-2, regulates the cell cycle. Cell 96:529–539PubMed
108.
Klionsky DJ, Meijer AJ, Codogno P (2005) Autophagy and p70S6 kinase. Autophagy 1:59–60, discussion 60-61PubMed
109.
Noda T, Ohsumi Y (1998) Tor, a phosphatidylinositol kinase homologue, controls autophagy in yeast. J Biol Chem 273:3963–3966PubMed
110.
Rubinsztein DC, Gestwicki JE, Murphy LO, Klionsky DJ (2007) Potential therapeutic applications of autophagy. Nat Rev Drug Discov 6:304–312PubMed
111.
Bjornsti MA, Houghton PJ (2004) The TOR pathway: a target for cancer therapy. Nat Rev Cancer 4:335–348PubMed
112.
Eshleman JS, Carlson BL, Mladek AC, Kastner BD, Shide KL, Sarkaria JN (2002) Inhibition of the mammalian target of rapamycin sensitizes U87 xenografts to fractionated radiation therapy. Cancer Res 62:7291–7297PubMed
113.
Paglin S, Hollister T, Delohery T, Hackett N, McMahill M, Sphicas E, Domingo D, Yahalom J (2001) A novel response of cancer cells to radiation involves autophagy and formation of acidic vesicles. Cancer Res 61:439–444PubMed
114.
Kanzawa T, Germano IM, Komata T, Ito H, Kondo Y, Kondo S (2004) Role of autophagy in temozolomide-induced cytotoxicity for malignant glioma cells. Cell Death Differ 11:448–457PubMed
115.
Opipari AW Jr, Tan L, Boitano AE, Sorenson DR, Aurora A, Liu JR (2004) Resveratrol-induced autophagocytosis in ovarian cancer cells. Cancer Res 64:696–703PubMed
116.
Kondo Y, Kanzawa T, Sawaya R, Kondo S (2005) The role of autophagy in cancer development and response to therapy. Nat Rev Cancer 5:726–734PubMed
117.
Lefranc F, Kiss R (2006) Autophagy, the Trojan horse to combat glioblastomas. Neurosurg Focus 20:E7PubMed
118.
Iwamaru A, Kondo Y, Iwado E, Aoki H, Fujiwara K, Yokoyama T, Mills GB, Kondo S (2007) Silencing mammalian target of rapamycin signaling by small interfering RNA enhances rapamycin-induced autophagy in malignant glioma cells. Oncogene 26:1840–1851PubMed
119.
Lefranc F, Facchini V, Kiss R (2007) Proautophagic drugs: a novel means to combat apoptosis-resistant cancers, with a special emphasis on glioblastomas. Oncologist 12:1395–1403PubMed
120.
Schweichel JU, Merker HJ (1973) The morphology of various types of cell death in prenatal tissues. Teratology 7:253–266PubMed
121.
Hoyer-Hansen M, Bastholm L, Szyniarowski P, Campanella M, Szabadkai G, Farkas T, Kianchi K, Fehrenbacher N, Elling F, Rizzuto R, Mathiasen IS, Jaattela M (2007) Control of macroautophagy by calcium, calmodulin-dependent kinase kinase-beta, and Bcl-2. Mol Cell 25:193–205PubMed
122.
Hoyer-Hansen M, Jaattela M (2007) Connecting endoplasmic reticulum stress to autophagy by unfolded protein response and calcium. Cell Death Differ 14:1576–1582PubMed
123.
Ozcan U, Ozcan L, Yilmaz E, Duvel K, Sahin M, Manning BD, Hotamisligil GS (2008) Loss of the tuberous sclerosis complex tumor suppressors triggers the unfolded protein response to regulate insulin signaling and apoptosis. Mol Cell 29:541–551PubMedPubMedCentral
Metadata
Title
Clinical and Molecular Insights into Tuberous Sclerosis Complex Renal Disease
Authors
Brian J. Siroky
Hong Yin
John J. Bissler
Publication date
01-06-2011
Publisher
Springer Berlin Heidelberg
Published in
Pediatric Nephrology / Issue 6/2011
Print ISSN: 0931-041X
Electronic ISSN: 1432-198X
DOI
https://doi.org/10.1007/s00467-010-1689-5

Other articles of this Issue 6/2011

Pediatric Nephrology 6/2011 Go to the issue

Original Article

Henoch-Schönlein purpura nephritis with nephrotic state in children: predictors of poor outcomes

Letter to the Editors

Pericardial tamponade in a child with nephrotic syndrome

Original Article

Growth of kidney-transplanted pediatric patients treated with sirolimus

Review

Uraemic vasculopathy in children with chronic kidney disease: prevention or damage limitation?

Original Article

Cyclophosphamide in steroid-dependent nephrotic syndrome

Letter to the Editors

Pauci-immune crescentic glomerulonephritis complicating Sjögren's syndrome in a 12-year-old girl